Table 2. Clinical characteristics of ALK-positive patients receiving ALK TKIs.
| Characteristics | Sequential therapy group, n (%) | Direct second-generation group, n (%) |
|---|---|---|
| Line of initial ALK TKI | ||
| First | 70 (60.9) | 71 (74.0) |
| Second or more | 45 (39.1) | 25 (26.0) |
| Best response under initial ALK TKI | ||
| Complete response | 1 (0.9) | 0 (0.0) |
| Partial response | 77 (67.0) | 71 (74.0) |
| Stable disease | 34 (29.6) | 23 (24.0) |
| Progressive disease | 3 (2.6) | 2 (2.1) |
| Second-generation ALK TKI | ||
| Alectinib | 62 (53.9) | 76 (79.2) |
| Brigatinib | 16 (13.9) | 2 (2.1) |
| Ceritinib | 17 (14.8) | 0 (0.0) |
| Others | 20 (17.4) | 18 (18.8) |
| Reason for second-generation ALK TKI discontinuation | ||
| Progression | 85 (73.9) | 47 (49.0) |
| Toxicity | 0 (0.0) | 2 (2.1) |
| Death | 3 (2.6) | 3 (3.1) |
| Ongoing | 27 (23.5) | 44 (45.8) |
| Median PFS (months, 95% CI) | 25.27 (22.12–28.42) | 20.47 (13.95–26.99) |
| 1-year PFS rate | 85.22% | 71.2% |
| 5-year PFS rate | 21.6% | 37.6% |
| Median OS (months, 95% CI) | 70.27 (51.08–89.46) | Not reached |
| 1-year OS rate | 96.5% | 93.6% |
| 5-year OS rate | 55.55% | 58.2% |
ALK, anaplastic lymphoma kinase; CI, confidence interval; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor.